OGEN (Oragenics Inc.) Net earnings per share (EPS TTM)

Oragenics Inc. (OGEN) - corporate logo

Oragenics, Inc. (OGEN) management is actively attracting investment to commercialize drugs for pulmonary infections. The fundamental TTM net income per share metric on the GURU.Markets chart confirms asset movement, where the -2.21 level reflects the current magnitude. Stable FCF is supported by patents for oral medications, while growth potential is based on unique intranasal delivery of neurosteroids for CNS injuries.

OGEN (oragenics.com) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

Oragenics (OGEN) - metric breakdowns and financial figures

- current quotes and average value forecast:
Fundamental company analysis:OGEN - oragenics.com
Flagship merchandise of oragenics.com

This indicator is calculated by dividing the aggregate net income over the last four quarters by the total number of shares outstanding. The metric determines the investor's actual equity return, reflecting the efficiency of capital generation. For Oragenics, Inc. (OGEN), this calculation confirms the monetization of its unique intranasal delivery method for neuroprotectors. Inelastic demand from the military and clinics provides potential for earnings growth. By analyzing the rolling earnings per share (EPS) figure, one can assess the sustainability of this fundamental momentum.